Xencor (XNCR) Getting Somewhat Positive News Coverage, Analysis Finds

Media coverage about Xencor (NASDAQ:XNCR) has been trending somewhat positive on Monday, Accern Sentiment reports. The research firm rates the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Xencor earned a news sentiment score of 0.12 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 44.6082977044169 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Here are some of the media headlines that may have impacted Accern’s analysis:

Xencor (XNCR) opened at $21.53 on Monday. Xencor has a 1 year low of $18.55 and a 1 year high of $28.64.

Several research firms recently commented on XNCR. BidaskClub lowered Xencor from a “sell” rating to a “strong sell” rating in a report on Friday. ValuEngine raised Xencor from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Zacks Investment Research downgraded Xencor from a “hold” rating to a “sell” rating in a research report on Saturday, November 11th. Piper Jaffray Companies reiterated a “buy” rating and set a $35.00 price target on shares of Xencor in a research report on Sunday, November 12th. Finally, Cantor Fitzgerald began coverage on Xencor in a research report on Wednesday, November 29th. They set an “overweight” rating and a $33.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $30.80.

In other news, major shareholder John S. Stafford III bought 9,215 shares of the firm’s stock in a transaction dated Thursday, December 14th. The shares were acquired at an average price of $20.76 per share, for a total transaction of $191,303.40. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder John S. Stafford III bought 24,653 shares of the firm’s stock in a transaction dated Wednesday, October 25th. The stock was purchased at an average price of $20.01 per share, for a total transaction of $493,306.53. The disclosure for this purchase can be found here. Insiders have acquired 278,535 shares of company stock worth $5,526,936 in the last quarter. 4.03% of the stock is currently owned by company insiders.

WARNING: “Xencor (XNCR) Getting Somewhat Positive News Coverage, Analysis Finds” was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this article on another domain, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this article can be accessed at https://sportsperspectives.com/2017/12/18/xencor-xncr-getting-somewhat-positive-news-coverage-analysis-finds.html.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Insider Buying and Selling by Quarter for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply